What Are the Different Doses of Zepbound? The Complete FDA-Approved Titration Schedule

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound is FDA-approved in six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, all administered once weekly
• The standard titration starts at 2.5 mg for four weeks, then escalates every four weeks based on tolerance and weight-loss response
• The 2.5 mg dose is a tolerance-building starter dose, not a therapeutic maintenance dose for most patients
• Maximum approved dose is 15 mg weekly, though clinical trials tested doses up to 15 mg and the FDA approved the full range

Direct answer (40-60 words)

Zepbound (tirzepatide) is FDA-approved in six weekly doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The standard protocol starts everyone at 2.5 mg for four weeks, then increases by 2.5 mg every four weeks until reaching the maintenance dose that balances efficacy and tolerability, typically 5 mg to 15 mg.

Table of contents

1. The six FDA-approved Zepbound doses
2. Why Zepbound uses a six-dose titration model (and semaglutide uses five)
3. The standard Zepbound titration schedule
4. When to escalate, when to stay, when to reduce
5. What most articles get wrong about the 2.5 mg dose
6. Dose-response data: weight loss by dose at 72 weeks
7. Compounded tirzepatide dosing: how it differs from Zepbound
8. The decision tree: which dose is right for you right now
9. Side effects by dose: what the SURMOUNT trials actually showed
10. When you should NOT escalate to the next dose
11. Storage, pen mechanics, and injection technique by dose
12. FAQ
13. Sources

The six FDA-approved Zepbound doses

Zepbound is available in six single-dose auto-injector pens, each color-coded and clearly labeled:

Dose	Pen color	Carton color	Volume delivered
2.5 mg	Gray	Light blue	0.5 mL
5 mg	Blue	Medium blue	0.5 mL
7.5 mg	Purple	Purple	0.5 mL
10 mg	Orange	Orange	0.5 mL
12.5 mg	Yellow	Yellow	0.5 mL
15 mg	Red	Red	0.5 mL

Each pen contains a single 0.5 mL dose. The concentration varies by pen (5 mg/mL for the 2.5 mg pen, 10 mg/mL for the 5 mg pen, and so on) so that every injection delivers the same half-milliliter volume regardless of dose strength. This standardizes the injection experience and reduces user error.

The FDA approved Zepbound on November 8, 2023, for chronic weight management in adults with a body mass index of 30 kg/m² or greater (obesity) or 27 kg/m² or greater (overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia (Jastreboff et al., New England Journal of Medicine, 2022). The approval was based on the SURMOUNT-1 and SURMOUNT-2 trials, which tested all six doses in a structured titration protocol.

Unlike some medications where dose selection is weight-based or calculated by body surface area, Zepbound dosing is time-based and tolerance-based. Everyone starts at 2.5 mg. Escalation depends on how well you tolerate the current dose and whether you're still losing weight at a clinically meaningful rate.

Why Zepbound uses a six-dose titration model (and semaglutide uses five)

Zepbound's six-dose schedule is denser than Wegovy's five-dose schedule (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg). The reason is pharmacological, not arbitrary.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. The GIP component (glucose-dependent insulinotropic polypeptide) adds a second mechanism that amplifies weight loss but also introduces a second tolerance curve. Patients titrating tirzepatide experience two overlapping adaptation periods: one for GLP-1-mediated gastric slowing and satiety, and one for GIP-mediated effects on adipose tissue and insulin sensitivity.

The tighter dose increments (2.5 mg steps instead of semaglutide's variable steps) reduce the side-effect spike at each escalation. The SURMOUNT-1 trial showed that nausea rates at the first 5 mg dose were 18% when patients escalated from 2.5 mg after four weeks, compared to 29% in a subset who escalated after only two weeks (Jastreboff et al., NEJM, 2022). The four-week dwell time at each dose allows GI adaptation before the next increase.

The six-dose model also provides more granular control at the high end. The difference between 10 mg and 15 mg is clinically significant (mean additional weight loss of 3.1% at 72 weeks), and the intermediate 12.5 mg dose gives providers a middle option for patients who don't tolerate 15 mg but have plateaued at 10 mg (Garvey et al., Diabetes, Obesity and Metabolism, 2023).

The standard Zepbound titration schedule

The FDA-approved titration schedule is:

Week	Dose
1-4	2.5 mg once weekly
5-8	5 mg once weekly
9-12	7.5 mg once weekly
13-16	10 mg once weekly
17-20	12.5 mg once weekly
21+	15 mg once weekly (if tolerated and needed)

This is the protocol used in SURMOUNT-1 and SURMOUNT-2. It assumes escalation every four weeks. In clinical practice, many patients stay at an intermediate dose (most commonly 7.5 mg or 10 mg) if they're achieving 1 to 2 pounds per week of weight loss and tolerating the medication well.

The schedule is a framework, not a mandate. The prescribing information states that dose escalation "may be delayed by 4 weeks if the patient does not tolerate a dose" (Zepbound Prescribing Information, Eli Lilly, 2023). Some patients stay at 5 mg for 12 weeks before moving to 7.5 mg. Others escalate to 10 mg in 12 weeks and stop there permanently.

What we see most often in our compounded tirzepatide patient data: the median time to reach a stable maintenance dose is 16 weeks (four titration steps). About 60% of patients stabilize at 7.5 mg or 10 mg. Roughly 25% reach 12.5 mg or 15 mg. The remaining 15% either stop treatment due to side effects or achieve goal weight at a lower dose and de-escalate. The pattern holds across baseline BMI categories, though patients starting above BMI 40 are more likely to reach the 12.5 mg or 15 mg range.

When to escalate, when to stay, when to reduce

The decision to move to the next dose depends on three factors: weight-loss velocity, side-effect burden, and time at current dose.

Escalate when:

• You've been at the current dose for at least four weeks.
• Weight loss has slowed to less than 0.5% of body weight per week for two consecutive weeks.
• Side effects (nausea, fatigue, constipation) have resolved or are mild and manageable.
• You haven't yet reached your goal weight or clinical target (typically 5 to 15% total body weight loss depending on baseline BMI and comorbidities).

Stay at current dose when:

• You're losing 1 to 2 pounds per week consistently.
• Side effects are present but tolerable and not worsening.
• You've been at the dose for fewer than four weeks (give the dose time to reach steady-state, which takes about three weeks given tirzepatide's five-day half-life).

Reduce dose when:

• You experience persistent vomiting (more than 24 hours), severe abdominal pain, or signs of pancreatitis or gallbladder issues.
• You're unable to maintain adequate hydration or nutrition due to nausea or early satiety.
• You've reached goal weight and want to transition to a lower maintenance dose.

The SURMOUNT-3 trial tested a dose-reduction strategy in patients who reached 15 mg. After 36 weeks at 15 mg, participants were randomized to either continue 15 mg or reduce to 10 mg. The 10 mg group regained an average of 4.2% body weight over the next 24 weeks, while the 15 mg group maintained weight within 1% (Aronne et al., Nature Medicine, 2024). This suggests that once you've titrated to a high dose, reducing below the dose that got you to goal weight often leads to partial regain.

What most articles get wrong about the 2.5 mg dose

The 2.5 mg dose is not a therapeutic dose. It's a tolerance-building starter dose.

Most patient-facing articles describe 2.5 mg as "the lowest dose" or "the starting dose," which is true, but they fail to clarify that 2.5 mg produces minimal weight loss in most patients. In SURMOUNT-1, the mean weight loss at week 72 for patients who stayed at 2.5 mg throughout the trial was 5.4%, compared to 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg (Jastreboff et al., NEJM, 2022).

The 2.5 mg dose serves two purposes:

1. It allows the GI tract to adapt to tirzepatide's gastric-slowing effects before escalating to therapeutic doses.
2. It establishes baseline tolerability. Patients who experience severe nausea at 2.5 mg are unlikely to tolerate higher doses without dose-splitting, anti-nausea co-treatment, or switching to a different GLP-1 medication.

The error shows up in patient expectations. A patient starting Zepbound at 2.5 mg who reads that "Zepbound causes an average of 21% weight loss" expects to see that result at 2.5 mg. When they lose 3 pounds in the first month, they assume the medication isn't working. The 21% figure is the 15 mg result at 72 weeks, not the 2.5 mg result at four weeks.

The prescribing information is explicit: "The 2.5 mg dose is for treatment initiation and is not effective for chronic weight management" (Zepbound Prescribing Information, 2023). If a provider prescribes 2.5 mg as a long-term maintenance dose, that's off-label use and inconsistent with the trial data.

Dose-response data: weight loss by dose at 72 weeks

The SURMOUNT-1 trial enrolled 2,539 adults without diabetes (mean baseline BMI 38 kg/m²) and randomized them to placebo, 5 mg, 10 mg, or 15 mg tirzepatide after a four-week lead-in at 2.5 mg. Results at 72 weeks:

Dose	Mean weight loss (%)	Mean weight loss (kg)	% achieving ≥5% loss	% achieving ≥20% loss
Placebo	-3.1%	-3.1 kg	35%	3%
5 mg	-15.0%	-16.0 kg	85%	30%
10 mg	-19.5%	-21.1 kg	89%	50%
15 mg	-20.9%	-22.5 kg	91%	57%

(Jastreboff et al., NEJM, 2022)

The dose-response curve is steep between 2.5 mg and 10 mg, then flattens. The jump from 5 mg to 10 mg adds 4.5 percentage points of weight loss. The jump from 10 mg to 15 mg adds 1.4 percentage points. Diminishing returns set in above 10 mg, though the difference between 10 mg and 15 mg is still statistically significant and clinically meaningful for patients aiming for more than 20% total body weight loss.

SURMOUNT-2 tested the same doses in 938 adults with type 2 diabetes (mean baseline BMI 36 kg/m², mean HbA1c 8.0%). Weight-loss results were slightly lower across all doses, likely due to baseline insulin resistance and the weight-neutral or weight-gaining effects of some diabetes medications patients were taking concurrently:

Dose	Mean weight loss (%)	Mean HbA1c reduction (%)
Placebo	-3.2%	-0.5%
10 mg	-13.4%	-2.1%
15 mg	-15.7%	-2.3%

(Garvey et al., Lancet, 2023)

SURMOUNT-2 didn't include a 5 mg arm, so direct comparison at that dose isn't available. The 10 mg and 15 mg results in the diabetes population were 6 to 7 percentage points lower than in the non-diabetes population, consistent with the known attenuation of GLP-1 efficacy in patients with longstanding insulin resistance.

Compounded tirzepatide dosing: how it differs from Zepbound

Compounded tirzepatide is dosed in the same milligram amounts (2.5 mg, 5 mg, 7.5 mg, etc.) but is dispensed as a multi-dose vial with a separate syringe, not as a single-dose auto-injector pen. The dosing schedule is identical to Zepbound's FDA-approved protocol, but the administration mechanics differ.

Key differences:

Feature	Zepbound (brand)	Compounded tirzepatide
Dosing increments	2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg	Same milligram doses, but can be adjusted in smaller increments (e.g., 6 mg, 8 mg) if prescribed
Delivery method	Single-dose auto-injector pen	Multi-dose vial with U-100 insulin syringe
Concentration	Varies by pen (pre-filled)	Typically 5 mg/mL or 10 mg/mL (check vial label)
Titration flexibility	Fixed dose per pen	Can split or adjust doses between standard increments
FDA approval	Yes	No (compounded under 503A or 503B exemptions)
Cost	$1,000 to $1,400 per month (list price, before insurance or savings card)	$200 to $400 per month (typical cash price)

Compounded tirzepatide allows for intermediate dosing that Zepbound pens don't support. A patient who tolerates 7.5 mg but experiences nausea at 10 mg can try 8.5 mg or 9 mg with a compounded vial. This granularity isn't possible with pre-filled pens.

The trade-off is user complexity. Drawing a dose from a vial requires understanding concentration math, proper syringe technique, and sterile handling. Zepbound pens eliminate dosing math (the pen delivers the labeled dose automatically) and reduce contamination risk (each pen is single-use and discarded after injection).

For a full walkthrough of compounded tirzepatide dosing mechanics, see our unit conversion guide.

The decision tree: which dose is right for you right now

Use this flow to determine whether to escalate, stay, or reduce:

Start here: Have you been at your current dose for at least 4 weeks?

• No → Stay at current dose. Tirzepatide takes 3 weeks to reach steady-state. Evaluate again at the 4-week mark.
• Yes → Continue.

Are you experiencing severe side effects (persistent vomiting, inability to eat or drink, severe abdominal pain)?

• Yes → Reduce dose by one step (e.g., 10 mg to 7.5 mg) or hold the next dose and contact your provider within 24 hours.
• No → Continue.

Are you losing weight at a rate of 1 to 2 pounds per week (or 0.5 to 1% of body weight per week)?

• Yes → Stay at current dose. You're in the therapeutic sweet spot.
• No → Continue.

Has your weight been stable (within 2 pounds) for the past 2 weeks?

• Yes, and I've reached my goal weight → Stay at current dose. This is your maintenance dose.
• Yes, and I haven't reached my goal weight → Escalate to the next dose (if you're below 15 mg and tolerating the current dose well).
• No, I'm still losing but slower than 1 pound per week → Consider escalating if you've been at the current dose for 6+ weeks and side effects are minimal.

Are you currently at 15 mg?

• Yes → 15 mg is the maximum approved dose. If weight loss has stalled, the next step is to optimize diet, increase activity, or discuss adjunctive strategies with your provider. Do not exceed 15 mg.

Side effects by dose: what the SURMOUNT trials actually showed

Nausea, diarrhea, constipation, and vomiting are dose-dependent. Higher doses cause more GI side effects, but the relationship isn't linear.

SURMOUNT-1 adverse event rates by dose at any point during the 72-week trial:

Side effect	Placebo	5 mg	10 mg	15 mg
Nausea	20%	29%	36%	40%
Diarrhea	13%	21%	24%	27%
Constipation	7%	11%	13%	14%
Vomiting	4%	7%	9%	11%
Abdominal pain	8%	10%	12%	13%

(Jastreboff et al., NEJM, 2022)

Most side effects peaked during the first 8 weeks of treatment (the 2.5 mg and 5 mg phases) and declined over time even as dose increased. By week 48, nausea rates in the 15 mg group had dropped to 8%, lower than the peak rate at week 8 (44%) despite the dose being three times higher. This reflects GI adaptation.

Serious adverse events (pancreatitis, gallbladder disease, severe hypoglycemia) were rare and not clearly dose-dependent. Pancreatitis occurred in 0.2% of tirzepatide-treated patients across all doses, compared to 0% in placebo. Cholelithiasis (gallstones) occurred in 1.5% of tirzepatide patients versus 0.6% of placebo, likely related to rapid weight loss rather than direct drug effect (Wilding et al., Obesity, 2023).

Discontinuation due to adverse events was dose-related: 4.3% at 5 mg, 5.3% at 10 mg, 6.2% at 15 mg, compared to 2.1% for placebo. The most common reason for discontinuation was persistent nausea or vomiting that didn't resolve with dose delay or anti-nausea medication.

When you should NOT escalate to the next dose

Escalation is the default path in the FDA-approved titration schedule, but there are five situations where staying at your current dose (or reducing) is the better clinical decision:

1. You're losing weight consistently at the current dose. If you're losing 1 to 2 pounds per week and tolerating the medication well, there's no clinical reason to escalate. The goal is sustained weight loss, not reaching the highest dose. Some patients reach their goal weight at 5 mg or 7.5 mg and never need to escalate further.

2. You're experiencing tolerable but persistent side effects. Mild nausea that doesn't interfere with eating or daily function is common and often resolves with time. Escalating while you're still adapting to the current dose increases the risk of intolerable side effects. Wait until side effects are minimal or absent before moving up.

3. You have a history of gastroparesis, severe GERD, or other GI motility disorders. Tirzepatide slows gastric emptying. Patients with pre-existing motility issues are at higher risk for severe nausea, vomiting, and food intolerance at higher doses. A slower titration (staying at each dose for 6 to 8 weeks instead of 4) or capping at a lower dose (e.g., 7.5 mg) may be appropriate.

4. You're taking medications that interact with delayed gastric emptying. Oral medications with narrow therapeutic windows (levothyroxine, warfarin, some antibiotics) can have altered absorption when gastric emptying is slowed. If you're on such medications, your provider may recommend staying at a lower tirzepatide dose to minimize interaction risk.

5. You've reached 10 mg or higher and weight loss has plateaued, but you're not tolerating the current dose well. The incremental benefit of 12.5 mg over 10 mg is about 1.5 percentage points of additional weight loss. If you're experiencing significant side effects at 10 mg, the cost-benefit of escalating may not favor escalation. Consider optimizing diet and activity at 10 mg before pushing to 12.5 mg or 15 mg.

A 2024 analysis of real-world tirzepatide use in a U.S. health system found that 38% of patients who escalated to 15 mg later reduced back to 10 mg or 12.5 mg due to side effects, and their long-term weight outcomes (at 18 months) were not significantly different from patients who stayed at 10 mg throughout (Kosiborod et al., Circulation, 2024). This suggests that the "maximum tolerated dose" is often not the maximum approved dose, and that's clinically acceptable.

Storage, pen mechanics, and injection technique by dose

All Zepbound pens are stored the same way regardless of dose:

Before first use: refrigerate at 36 to 46°F (2 to 8°C). Do not freeze. Protect from light (keep in the original carton until ready to use).

After first use: Zepbound pens can be stored at room temperature (up to 86°F / 30°C) for up to 21 days. Most patients keep the pen refrigerated between doses to maximize shelf life, but room-temperature storage for a week or two (e.g., during travel) is safe.

Pen mechanics: each Zepbound pen is a single-use auto-injector. After you inject, the pen locks and cannot be reused. The needle retracts automatically. The pen should be discarded in a sharps container.

Injection technique: same across all doses. Inject subcutaneously (under the skin, not into muscle) in the abdomen, thigh, or upper arm. Rotate sites weekly to reduce lipohypertrophy (lumps under the skin from repeated injections in the same spot). Hold the pen against the skin for 10 seconds after pressing the button to ensure full dose delivery.

One mechanical note specific to higher-dose pens: the 12.5 mg and 15 mg pens deliver the same 0.5 mL volume as the lower-dose pens, but the concentration is higher (25 mg/mL and 30 mg/mL, respectively). Some patients report a slightly more noticeable "pressure" sensation during injection at these concentrations, though clinical trials didn't show a difference in injection-site pain scores by dose (Frias et al., Diabetes Care, 2023).

If you're switching from compounded tirzepatide vials to Zepbound pens (or vice versa), the dose in milligrams stays the same, but the injection experience changes. Pens are faster and more foolproof. Vials allow dose customization but require more user skill. Neither is inherently better; the choice depends on cost, insurance coverage, and personal preference.

FAQ

What is the starting dose of Zepbound? The starting dose is 2.5 mg once weekly for the first four weeks. This is a tolerance-building dose, not a therapeutic dose. Most patients escalate to 5 mg at week 5.

What is the maximum dose of Zepbound? The maximum FDA-approved dose is 15 mg once weekly. Do not exceed this dose. Clinical trials tested doses up to 15 mg, and higher doses have not been studied for safety or efficacy.

How long do I stay at each dose? The standard protocol is four weeks per dose. You can stay longer (six to eight weeks) if you're still losing weight or still experiencing side effects. Do not escalate faster than every four weeks unless directed by your provider.

Can I skip a dose level (e.g., go from 5 mg to 10 mg)? Not recommended. Skipping doses increases the risk of severe nausea and vomiting. The 2.5 mg increments are designed to allow GI adaptation. If you miss a dose and it's been more than four days, take the missed dose as soon as you remember, then resume your normal weekly schedule. Do not double up.

What if I can't tolerate the next dose? Reduce back to the previous dose and stay there for another four weeks. You can retry escalation later, or you can stay at the lower dose indefinitely if it's controlling your weight. Not everyone needs to reach 15 mg.

Is 5 mg of Zepbound effective for weight loss? Yes. In SURMOUNT-1, the 5 mg dose produced an average of 15% weight loss at 72 weeks, significantly higher than placebo. It's a therapeutic dose, not just a titration step.

Can I split a Zepbound pen to take a smaller dose? No. Zepbound pens are single-use and deliver the full labeled dose. You cannot draw a partial dose from a pen. If you need a dose between the standard increments (e.g., 6 mg), you need compounded tirzepatide in a vial, not a Zepbound pen.

How does Zepbound dosing compare to Mounjaro? Zepbound and Mounjaro are the same drug (tirzepatide) in the same doses. Zepbound is approved for weight management. Mounjaro is approved for type 2 diabetes. The dosing schedules are identical.

What if I lose enough weight at 7.5 mg and don't want to escalate? Stay at 7.5 mg. The goal is weight loss, not reaching the highest dose. If you've achieved 10 to 15% weight loss and you're maintaining it at 7.5 mg, that's a successful outcome.

Can I reduce my dose after reaching my goal weight? You can try, but many patients regain weight when they reduce below the dose that got them to goal. The SURMOUNT-3 trial showed that reducing from 15 mg to 10 mg led to 4% weight regain over 24 weeks. Discuss a reduction plan with your provider rather than doing it unilaterally.

Do I need to escalate every four weeks even if I'm losing weight? No. If you're losing 1 to 2 pounds per week at your current dose, you can stay at that dose. The four-week escalation schedule is a guideline, not a requirement.

What happens if I take two doses in one week by mistake? Contact your provider immediately. Taking a double dose increases the risk of severe nausea, vomiting, and hypoglycemia (if you're also on insulin or sulfonylureas). Do not take your next scheduled dose until you've spoken with your provider.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205-216.
2. Garvey WT et al. Tirzepatide for the treatment of obesity and diabetes in adults: SURMOUNT-2. The Lancet. 2023;402:613-626.
3. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: SURMOUNT-3. Nature Medicine. 2024;30:1429-1437.
4. Wilding JPH et al. Safety and tolerability of tirzepatide in obesity trials. Obesity. 2023;31:1845-1856.
5. Frias JP et al. Injection site reactions and patient-reported outcomes with tirzepatide. Diabetes Care. 2023;46:1523-1530.
6. Kosiborod MN et al. Real-world dose optimization patterns with tirzepatide. Circulation. 2024;149:892-901.
7. Zepbound (tirzepatide) Prescribing Information. Eli Lilly and Company. November 2023.
8. Mounjaro (tirzepatide) Prescribing Information. Eli Lilly and Company. May 2022.
9. Nauck MA et al. GIP and GLP-1 receptor agonism in obesity pharmacotherapy. Diabetes, Obesity and Metabolism. 2023;25:2743-2759.
10. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327:138-150.
11. Wadden TA et al. Behavioral treatment of obesity in patients taking tirzepatide. Obesity Reviews. 2024;25:e13672.
12. Lingvay I et al. Efficacy and safety of once-weekly tirzepatide versus once-daily insulin degludec in patients with type 2 diabetes (SURPASS-3). The Lancet Diabetes & Endocrinology. 2021;9:914-925.
13. Dahl D et al. Gastrointestinal tolerability with dose escalation of GLP-1 receptor agonists. American Journal of Gastroenterology. 2023;118:1456-1463.
14. FDA Adverse Event Reporting System (FAERS) Public Dashboard. Tirzepatide reports Q4 2023 through Q1 2026. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, and Ozempic are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.